Media reports say Merck is in talks to acquire Revolution Medicines in a potential $28–32 billion deal, a story that has fueled speculation about consolidation to refill oncology pipelines ahead of patent cliffs. Other suitors are reportedly interested, and industry sources caution discussions remain preliminary. The deal would provide access to Revolution’s RAS‑pathway assets, including late‑stage daraxonrasib. The coverage follows broader M&A signaling in oncology where large pharma pursue small biotechs with differentiated targeted therapies. Bid competition and the potential price tag reflect strategic urgency to secure next‑generation oncology assets as major blockbusters approach loss of exclusivity. Investors and executives will watch for definitive terms and target responses; a consummated transaction at reported valuations would be among the largest biotech takeovers outside recent mega‑deals.